Background: Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine’s immunogenicity and safety, especially in patients with pre-existing inflammatory conditions. Methods: Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021. Results: Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19–84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1–14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%). Conclusion: Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome.

Ocular inflammatory events following COVID-19 vaccination: a multinational case series / Testi, I.; Brandao-de-Resende, C.; Agrawal, R.; Pavesio, C.; Steeples, L.; Balasubramaniam, B.; Mccluskey, P.; Pichi, F.; Agarwal, A.; Herbort, C.; Cimino, L.; Iriqat, S.; Thorne, J. E.; Echegaray, J.; Babu, K.; Bialasiewicz, A. A.; Goldstein, D. A.; Ghadiri, N.; Calduch, A. F.; Andrade, G. C.; Mahendradas, P.; Gonzalez-Lopez, J. J.; Carreno, E.; Hamam, R. N.; Stubiger, N.; Bodaghi, B.; Chao, Y. -J.; Takeuchi, M.; Tay-Kearney, M. -L.; Portero, A.; Keino, H.; Esteban-Ortega, M.; Przezdziecka-Dolyk, J.; Radosavljevic, A.; Paredes, I.; Ling, H. S.; Kiong, W.; Tien, M.; Ng, X. L.; Pavesio, C.; Chee, S. P.; Siak, J.; Hernanz-Rodriguez, I.; Menezo, V.; Tappeiner, C.; Cruz, F. M.; Addison, P.; Kuijpers, R.; Vasconcelos-Santos, D. V.. - In: JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION. - ISSN 1869-5760. - 12:1(2022), pp. 4-N/A. [10.1186/s12348-021-00275-x]

Ocular inflammatory events following COVID-19 vaccination: a multinational case series

Cimino L.;
2022

Abstract

Background: Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine’s immunogenicity and safety, especially in patients with pre-existing inflammatory conditions. Methods: Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021. Results: Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19–84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1–14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%). Conclusion: Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome.
2022
12
1
4
N/A
Ocular inflammatory events following COVID-19 vaccination: a multinational case series / Testi, I.; Brandao-de-Resende, C.; Agrawal, R.; Pavesio, C.; Steeples, L.; Balasubramaniam, B.; Mccluskey, P.; Pichi, F.; Agarwal, A.; Herbort, C.; Cimino, L.; Iriqat, S.; Thorne, J. E.; Echegaray, J.; Babu, K.; Bialasiewicz, A. A.; Goldstein, D. A.; Ghadiri, N.; Calduch, A. F.; Andrade, G. C.; Mahendradas, P.; Gonzalez-Lopez, J. J.; Carreno, E.; Hamam, R. N.; Stubiger, N.; Bodaghi, B.; Chao, Y. -J.; Takeuchi, M.; Tay-Kearney, M. -L.; Portero, A.; Keino, H.; Esteban-Ortega, M.; Przezdziecka-Dolyk, J.; Radosavljevic, A.; Paredes, I.; Ling, H. S.; Kiong, W.; Tien, M.; Ng, X. L.; Pavesio, C.; Chee, S. P.; Siak, J.; Hernanz-Rodriguez, I.; Menezo, V.; Tappeiner, C.; Cruz, F. M.; Addison, P.; Kuijpers, R.; Vasconcelos-Santos, D. V.. - In: JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION. - ISSN 1869-5760. - 12:1(2022), pp. 4-N/A. [10.1186/s12348-021-00275-x]
Testi, I.; Brandao-de-Resende, C.; Agrawal, R.; Pavesio, C.; Steeples, L.; Balasubramaniam, B.; Mccluskey, P.; Pichi, F.; Agarwal, A.; Herbort, C.; Cimino, L.; Iriqat, S.; Thorne, J. E.; Echegaray, J.; Babu, K.; Bialasiewicz, A. A.; Goldstein, D. A.; Ghadiri, N.; Calduch, A. F.; Andrade, G. C.; Mahendradas, P.; Gonzalez-Lopez, J. J.; Carreno, E.; Hamam, R. N.; Stubiger, N.; Bodaghi, B.; Chao, Y. -J.; Takeuchi, M.; Tay-Kearney, M. -L.; Portero, A.; Keino, H.; Esteban-Ortega, M.; Przezdziecka-Dolyk, J.; Radosavljevic, A.; Paredes, I.; Ling, H. S.; Kiong, W.; Tien, M.; Ng, X. L.; Pavesio, C.; Chee, S. P.; Siak, J.; Hernanz-Rodriguez, I.; Menezo, V.; Tappeiner, C.; Cruz, F. M.; Addison, P.; Kuijpers, R.; Vasconcelos-Santos, D. V.
File in questo prodotto:
File Dimensione Formato  
s12348-021-00275-x.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 457.08 kB
Formato Adobe PDF
457.08 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1280720
Citazioni
  • ???jsp.display-item.citation.pmc??? 44
  • Scopus 56
  • ???jsp.display-item.citation.isi??? 54
social impact